Skip to main content
Premium Trial:

Request an Annual Quote

Consultancy Buys Majority Stake in Proteomics Shop BioMachines

This article has been updated to correct the spelling of Larrichio's former company.


NEW YORK, Feb. 1 (GenomeWeb News) - Clearview Limited, a Raleigh, NC-based consulting and advisory firm, has purchased a majority stake in BioMachines, a sample prep proteomics company located in Research Triangle Park, NC, the companies said today.


Clearview's stake gives the company "full transactional authority. It is less than 75 percent and greater than 60" said Biomachines' new chairman, Sam Tetlow.


Tetlow added that the acquisition "delivers a new commercial focus to the company," which has been developing products for five years.


The acquisition took place on Dec. 29, 2005, but was disclosed today to coincide with the release of BioMachine's new TMiD MALDI, Tetlow told GenomeWeb News.


Tetlow is the founding partner of Clearview and a principal with Research Triangle Ventures.


Tom Larrichio, a former vice president at TriVirix International, has been named CEO.


Additional details were not provided.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.